# Pectoralis major myofascial flap in salvage laryngectomy

E CÖMERT $^1$ , Ü TUNÇEL $^1$ , M TANER TORUN $^2$ , C KILIÇ $^3$ , A BUĞRA CENGIZ $^1$ , Z ŞENCAN $^1$ , M KAYA $^1$ 

<sup>1</sup>Department of Otolaryngology, Ankara Oncology Education and Research Hospital, <sup>2</sup>Department of Otolaryngology, Faculty of Medicine, Erzincan University, and <sup>3</sup>Department of Otolaryngology, Faculty of Medicine, Ordu University, Turkey

#### **Abstract**

Objective: The main purpose of this study was to evaluate the effect of the pectoralis major myofascial flap on pharyngocutaneous fistula formation and time to oral feeding.

*Methods*: This retrospective study reviewed 155 total laryngectomies. Patients were divided into two main groups. Group 1 included 110 patients who were treated primarily by total laryngectomy and group 2 comprised 45 patients who were treated by salvage laryngectomy with or without a pectoralis major myofascial flap.

Results: The use of a pectoralis major myofascial flap did not have a significant effect on pharyngocutaneous fistula formation in the salvage group (p = 0.376). When comparing the oral feeding day of patients with pharyngocutaneous fistula, a significant difference was observed between the salvage group with pectoralis major myofascial flap reinforcement and the salvage group without pectoralis major myofascial flap reinforcement (p = 0.004).

Discussion: Our study demonstrated that pectoralis major myofascial flap reinforcement did not decrease the rate of pharyngocutaneous fistula formation. Instead, it prevented the formation of large fistulas that would require surgical management, and showed a similar time to oral feeding and length of hospital stay to primary laryngectomy.

Key words: Salvage Therapy; Laryngectomy; Fistula; Pectoralis Muscles

## Introduction

Laryngeal carcinoma represents 2.2 per cent of all cancers. The treatment modalities for laryngeal carcinoma, especially in its early stages, are mainly based on tumour eradication with conservation of function. In advanced-stage tumours, surgical treatment cannot achieve good functional results. Organ preservation protocols, including radiotherapy and chemotherapy, have been widely used as an alternative to surgical treatment in advanced-stage tumours. Surgical treatment as salvage surgery is preferred in the case of tumour recurrence.

Pre-operative radiotherapy gradually increases postoperative complications. The most common complication seen after salvage laryngectomy is pharyngocutaneous fistula formation.<sup>5–7</sup> The rate of pharyngocutaneous fistula formation increases if salvage surgery is performed within the first year after radiotherapy.<sup>8</sup> Such a complication results in increased morbidity, and prolonged hospitalisation and greater hospital care expenditure.<sup>9,10</sup> The incidence of pharyngocutaneous fistula formation reported in the literature is extremely variable, ranging from 5 to 65 per cent. 9-11 To deal with this significant post-operative morbidity, several authors have advocated the routine use of non-irradiated tissues to reinforce the neopharynx. Pectoralis major myofascial flaps, sternocleidomastoid muscle collar flaps, latissimus dorsi flaps, deltopectoral flaps and free flaps have been used for reinforcement. 8,12,13

Since it was first described in 1979, the pectoralis major myocutaneous flap has been used widely in head and neck reconstruction, and also in the reconstruction of pharyngocutaneous fistulas. <sup>14</sup> In contrast, the pectoralis major myofascial flap has been used to prevent fistula formation in salvage laryngectomy. The main purpose of this study was to evaluate the effect of the pectoralis major myofascial flap on pharyngocutaneous fistula formation and time to oral feeding.

#### Materials and methods

This retrospective study reviewed 155 total laryngectomies performed between 2005 and 2012. All patients

Accepted for publication 16 September 2013 First published online 15 July 2014

suffered from  $T_3$ – $T_4$ -staged squamous cell carcinoma of the larynx. Subjects who underwent laryngopharyngectomy were not included in the study. Patients were divided into two groups according to their initial therapy. Group 1 included 110 patients who were treated primarily by total laryngectomy and unilateral or bilateral functional or modified radical neck dissection. Group 2 included 45 patients with recurrent disease after radical dose radiotherapy with cisplatin-based chemotherapy for  $T_3$ – $T_4$  laryngeal carcinoma and who were treated by salvage laryngectomy.

Since 2009, we began to use the pectoralis major myofascial flap as a second layer over the neopharynx after primary closure. Therefore, we divided group 2 into two subgroups: patients who underwent only primary closure (group 2a) and patients who underwent primary closure with a pectoralis major myofascial flap used to buttress the pharyngeal suture line (group 2b).

All data were gathered from patient charts and electronic medical records. Pharyngocutaneous fistula formation was categorised as wound dehiscence in the neopharynx region resulting in a fistula. Detailed demographic information was obtained including prior disease and surgeries, pre-operative treatment, duration and treatment of fistula, and time to oral feeding. The oral feeding day was considered to be the first day of oral nutrition after healing of the fistula.

Intra-operative and post-operative antibiotics – clindamycin phosphate 600 mg four times per day and amikacin 500 mg twice daily – were given to all patients for 7 days and additional doses or antibiotics were given when required during the treatment. Closure of the pharynx was performed in two layers, using 3-0 Vicryl® suture: an inner interrupted submucosal layer with inversion of the mucosa, and an outer interrupted layer with the inferior constrictor muscle. The suture line was T- or Y-shaped according to the less tension technique, and differed in relation to the extent of excised and remaining pharyngeal wall. A primary tracheoesophageal puncture was performed in all patients and a nasogastric feeding tube was inserted into the puncture site. Feeding started through the tube on the day after the operation. Oral feeding was attempted on the 10th day post-operatively in both groups. It was continued if there was no evidence of fistula and stopped if a fistula was suspected on clinical examination.

All of the cases with fistula were initially managed conservatively by stopping oral feeding, draining the wound by the removal of three or four stitches, debriding the fistula tract, administering broad-spectrum antibiotics recommended after wound culture was performed and applying a light compression dressing over the fistula site. If the defect was small (less than 2 cm), healing occurred or saliva leakage progressively decreased over the following week, conservative management continued and the patient began oral feeding 1 week after healing of the tract.

If the defect was large (greater than 2 cm) and the leakage persisted despite conservative management,

the pharyngocutaneous fistula was reconstructed with a pectoralis major myocutaneous flap as a second procedure. Repair of the pharyngocutaneous fistula was performed after maturation of the fistula margins to try to ensure that further wound breakdown would not occur. A skin paddle with a length similar to that of the defect was cut into a trapezium shape. It was harvested with its intact vascular pedicle, then subcutaneous tunnelling was performed at the chest-neck junction and the flap was dragged carefully to the neck. The cutaneous part of the flap was inverted to close the defect and the margins of the lateral skin flap were sutured to the edges of the defect. The muscular parts of the flap were then sutured to the base of the tongue, the ipsilateral and contralateral sternocleidomastoid muscles and the anterolateral section of the cervical oesophagus.

After 2009, pectoralis major myofascial flap reinforcement was performed as a second layer over the pharyngeal closure sutures after primary closure of the neopharynx. At the same time as the total laryngectomy, the pectoralis major muscle was harvested from the chest and laid down over the suture line of the pharynx. The flap was sutured to the base of the tongue, the ipsilateral and contralateral sternocleidomastoid muscles and the anterolateral section of the cervical oesophagus.

All procedures contributing to this work complied with the ethical standards of the relevant national and institutional guidelines on human experimentation (Ankara Oncology Education and Research Hospital, Turkey) and with the 1975 version of the Declaration of Helsinki, as revised in Seoul in 2008.

Statistical analyses were performed using the two-tailed Fisher's exact test from a  $2 \times 2$  contingency table or the chi-square test to determine whether the rate of pharyngocutaneous fistula formation was increased with previous chemoradiotherapy and reduced using the pectoralis major myofascial flap. Furthermore, we compared the pre-operative diseases, tracheotomy and post-operative oral feeding day in each group. Continuous variables were analysed with the *t*-test. For all analyses, a *p* value  $\leq 0.05$  was deemed statistically significant.

## **Results**

Group 1 consisted of 110 patients while group 2 comprised 45 patients. The median ages of the patients were 58 years (range: 37-70 years) for group 1 and 52 years (range: 42-68 years) for group 2. The female/male ratio was 5/105 and 1/44 for group 1 and 2, respectively. All of the patients had  $T_3-T_4$  squamous cell carcinoma of the larynx.

In group 1, 5 (4.5 per cent) patients were hypothyroid, 23 (20.9 per cent) had diabetes mellitus and 28 (25.4 per cent) had a pre-operative tracheotomy. Fourteen patients (12.7 per cent) had a previous failed attempt at partial laryngectomy. In group 2, 3 (6.6 per cent) patients were hypothyroid, 8 (17.7 per

TABLE I RATES OF PHARYNGOCUTANEOUS FISTULA FORMATION IN OUR PATIENT COHORT			
Characteristic	Group 1 $(n = 110)$	Group 2a $(n = 24)$	Group 2b $(n = 21)$
Pharyngocutaneous fistula Conservative management PMMC flap	18 (16.3%) 11 (10%) 7 (6.3%)	14 (58.3%) 4 (16.6%) 10 (41.6%)	9 (42.8%) 9 (42.8%) -*

\*None of the patients in group 2b required a second pectoralis major myocutaneous flap for pharyngocutaneous fistula reconstruction. PMMC = pectoralis major myocutaneous

	TABLE II		
POST-OPERATIVE ORAL FEEDI	NG DAY OF PATIENTS WIT	H PHARYNGOCUTANEOUS FISTU	JLA
Characteristic	Group 1	Group 2a	Group 2b
Conservative management, days (range) PMMC flap, days (range)	34.2 (28–43) 61.2 (42–78)	47.2 (34–60) 88.4 (56–142)	35.4 (26–52) _*

\*None of the patients in group 2b required a second pectoralis major myocutaneous flap for pharyngocutaneous fistula reconstruction. PMMC = pectoralis major myocutaneous

cent) had diabetes mellitus and 11 (24.4 per cent) had a pre-operative tracheotomy. None of the patients had a previous failed attempt at partial laryngectomy.

In group 1, 82 (74.5 per cent) patients underwent total laryngectomy with bilateral functional or modified radical neck dissection, while 28 (25.5 per cent) patients underwent total laryngectomy with unilateral radical neck dissection. In group 2, primary radiotherapy with curative intent in the range of 65–70 Gy was given, with primary cobalt radiotherapy laryngeal field only in 17 cases and laryngeal field with draining neck nodes in 28 cases, and with concomitant chemotherapy. Group 2a (primary closure only) consisted of 24 patients and group 2b (primary closure with pectoralis major myofascial flap) consisted of 21 patients.

Pharyngocutaneous fistula formation occurred between the 9th and 17th day post-operatively in 18 of the patients in group 1 (16.3 per cent). In 11 of these patients (61.1 per cent), complete healing of the defect occurred with conservative management. Seven patients (38.8 per cent) required a pectoralis major myocutaneous flap for reconstruction of the pharyngeal defect and this second operation was performed between the 17th and 24th day post-operatively. The flap was viable in all of the cases.

Pharyngocutaneous fistula formation occurred in 23 patients in group 2 (51.1 per cent). In group 2a, pharyngocutaneous fistula formation occurred in 14 (58.3 per cent) patients and 10 (71.4 per cent) of these required a pectoralis major myocutaneous flap for reconstruction of the pharyngeal defect. This second operation was performed between the 25th and 32nd day post-operatively. In group 2b, pharyngocutaneous fistula formation occurred in 9 (42.8 per cent) patients and all could be treated with conservative management. None of the patients in group 2b required a second flap for pharyngocutaneous fistula reconstruction. The rates of pharyngocutaneous fistula formation, the treatments used for each group and the post-operative oral feeding day are shown in Tables I and II.

Hypothyroidism (p = 0.803), diabetes mellitus (p = 0.502) and pre-operative tracheotomy (p = 0.674) did not have a significant effect on pharyngocutaneous fistula formation. The data on pre-operative conditions, fistula formation and its post-operative course are shown in Table III. The data on the oral feeding day and length of hospital stay for each group and subgroup are shown in Table IV. Previous chemoradiotherapy was significantly associated with fistula formation (p < 0.001) (Table III).

	TABLE III		
PRE-OPERATIVE CONDITIONS, FISTULA FORMATION AND POST-OPERATIVE COURSE OF FISTULAS IN GROUPS 1 AND 2 $$			
Variable	Group 1 $(n = 110)$	Group 2 $(n = 45)$	P
Hypothyroidism, $n$ (%)	5 (4.5)	3 (6.6)	0.803
Diabetes mellitus, $n$ (%)	23 (20.9)	8 (17.7)	0.502
Pre-operative tracheotomy, $n$ (%)	28 (25.4)	11 (24.4)	0.674
Pharyngocutaneous fistula, $n$ (%)	18 (16.3)	23 (51.1)	< 0.001
Fistulas requiring flap, $n$ (%)	7 (6.3)	10 (22.2)	0.510
Fistulas healing with conservative management, $n$ (%)	11 (10)	13 (28.8)	0.510
Oral feeding time in days, mean (SD)	15.6 (14.3)	35.8 (33.1)	< 0.001
Length of hospital stay in days, mean (SD)	20.7 (14.5)	41.2 (33.5)	< 0.001

TABLE IV POST-OPERATIVE COURSE OF FISTULAS IN GROUPS 2A AND 2B			
Variable	Group 2a (n = 24)	Group 2b ( <i>n</i> = 21)	P
Pharyngocutaneous fistula, $n$ (%) Fistulas healing with conservative management, $n$ (%) Fistulas requiring flap, $n$ (%) Oral feeding time in days, mean (SD) Length of hospital stay in days, mean (SD)	14 (58.3) 4 (16.6) 10 (41.6) 48.8 (39.4) 54.2 (39.5)	9 (42.8) 9 (42.8) -* 20.9 (13.8) 26.2 (14)	0.376 N/A N/A 0.004 0.004

<sup>\*</sup>None of the patients in group 2b required a second pectoralis major myocutaneous flap for pharyngocutaneous fistula reconstruction. N/A = not applicable; SD = standard deviation

TABLE V  ORAL FEEDING TIME AND LENGTH OF HOSPITAL STAY IN PATIENTS WITH PHARYNGOCUTANEOUS FISTULAS IN GROUPS 1 AND 2			
Variable	Group 1 ( <i>n</i> = 18)	Group 2 $(n = 23)$	P
Oral feeding time in days, mean (SD) Length of hospital stay in days, mean (SD)	44.7 (15.6) 50.2 (15.7)	60.5 (29.9) 66.3 (30)	0.05 0.046
SD = standard deviation			

TABLE VI  ORAL FEEDING TIME AND LENGTH OF HOSPITAL STAY IN PATIENTS WITH PHARYNGOCUTANEOUS FISTULAS IN GROUPS 2A AND 2B			
Variable	Group 2a ( <i>n</i> = 14)	Group 2b $(n = 9)$	P
Oral feeding time in days, mean (SD)	76.6 (27.6)	35.4 (7.7)	< 0.001
Length of hospital stay in days, mean (SD)	82.7 (27.6)	41 (7.5)	< 0.001
SD = standard deviation			

The use of a pectoralis major myofascial flap did not have a significant effect on pharyngocutaneous fistula formation (p = 0.376) in the salvage group (group 2). When comparing the oral feeding days of all patients included in the study, the differences between groups 1 and 2 (p < 0.001) and between groups 2a and 2b (p =0.004) were statistically significant. The oral feeding day and length of hospital stay of patients with pharyngocutaneous fistula formation in each group are shown in Tables V and VI. When comparing the oral feeding day of patients with pharyngocutaneous fistula, the differences between groups 1 and 2 ( $p \le 0.05$ ), groups 2a and 2b (p < 0.001) and groups 1 and 2a (p = 0.001)were statistically significant, whereas the differences between groups 1 and 2b were not statistically significant for the oral feeding day and length of hospital stay of patients with pharyngocutaneous fistula (p = 0.105and p = 0.109, respectively).

### **Discussion**

Pre-operative radiotherapy followed by salvage laryngectomy has been shown to be the most significant risk factor contributing to the development of pharyngocutaneous fistula. 15 Pharyngocutaneous fistulas develop earlier, tend to be larger and persist longer in pre-operatively irradiated patients. 15 One of the major problems in salvage patients is further wound breakdown after pharyngocutaneous fistula formation. The maturation of the fistula margins occurs later than in primary laryngectomy patients, therefore the repair of pharyngocutaneous fistulas is performed later and the cost of the treatment gradually increases as a result of prolonged hospital stay and additional surgery. The fistulas of irradiated patients usually require surgical closure whereas most of the fistulas of non-irradiated patients heal with conservative management. 15 In patients irradiated pre-operatively and in fistulas larger than 1 cm in diameter, surgical closure with primary closure, local flaps or free tissue transfer is often necessary. 16

Although radiotherapy with the concurrent administration of cisplatin-based chemotherapy is more effective than radiotherapy alone for larynx preservation and locoregional control, it is associated with a twofold increase in the incidence of pharyngocutaneous fistula. 8,17,18 Tumour–node–metastasis (TNM) staging, associated comorbidities, neck clearance, low levels of haemoglobin pre- and post-operatively, low serum albumin, previous tracheotomy, type of closure, duration of surgery and hypothyroidism have also been determined to be risk factors for pharyngocutaneous fistula. 12,19 In our study, all of the tumours were at an advanced stage and closure of the pharynx was performed in two layers with a T- or Y-shaped suture line. We examined the effect of chemoradiotherapy, hypothyroidism, diabetes mellitus and previous tracheotomy on pharyngocutaneous fistula formation and only pre-operative chemoradiotherapy was significantly associated with pharyngocutaneous fistula formation. The rates of fistula formation that we observed in primary total laryngectomy and salvage laryngectomy were similar to those reported in other studies.<sup>2</sup>

In recent studies, the use of non-irradiated flaps during initial surgery has been recommended to reduce the incidence rates and morbidities associated with salivary fistulas in salvage laryngectomy, even when there is sufficient mucosa for primary closure. <sup>21,22</sup> Usually, the choice of using a flap or not is based on the intra-operative preference and

judgement of the surgeon.<sup>12</sup> The main surgical principle is safe closure with well-vascularised tissue and without suture tension.

- Contrary to recent studies, our study showed that pectoralis major myofascial flap reinforcement did not decrease the rate of pharyngocutaneous fistula formation.
   Instead, it prevented the formation of large fistulas and provided similar time to oral feeding and length of hospital stay to primary laryngectomy patients
- In the salvage group with pectoralis major myofascial flap reinforcement, all of the fistulas healed with conservative management in a similar time to primary laryngectomy patients
- No significant difference was observed between the oral feeding day and length of hospital stay of patients who underwent primary laryngectomy and those who underwent salvage laryngectomy with pectoralis major myofascial flap

The pectoralis major myocutaneous flap has been demonstrated to be a reliable and versatile flap for reconstruction in the head and neck area, as it has been associated with a low incidence of complications.<sup>23</sup> One of the consequences of using pectoralis major myofascial flap reinforcement is the change in timing, indications present and flap composition compared with the standard pectoralis major myocutaneous flap. In this procedure, the flap is no longer considered to be a secondary treatment used for closure of the defect; instead, it is used during the initial operation to prevent the formation of a fistula. In a pectoralis major myocutaneous flap, the vitality of the cutaneous part, which is supplied by the microvascular vessels of the underlying muscle, determines the success of the reconstruction. In a pectoralis major myofascial flap, the flap only contains muscle and fascia tissues that are directly supplied from its pedicle. When a pectoralis major myocutaneous flap is used as a second procedure for reconstruction, total flap necrosis is the only complication that requires another flap.<sup>23</sup> However, when a pectoralis major myofascial flap is used during salvage laryngectomy, another cutaneous flap may be required in the case of formation of a large fistula. This is probably the most important disadvantage of the procedure. Although none of our patients required a second flap, the risk of a large fistula always exists in pre-operatively irradiated patients.

Righini *et al.* demonstrated a reduction in the rates of pharyngocutaneous fistula formation from 50 to 23 per cent by using pectoralis major myofascial flap reinforcement during salvage laryngectomy.<sup>24</sup> Their findings failed to reach statistical significance due to

their small sample size; however, they did suggest that the use of a pectoralis major myofascial flap would reduce the rate of pharyngocutaneous fistula formation in salvage surgery. 24 Smith et al. compared their results for pectoralis major myofascial flaps with those of an historical cohort that was surgically treated without pectoralis major myofascial flaps and reported a significant reduction in the rate of pharyngocutaneous fistula formation (from 23 to 1 per cent). They concluded that the pectoralis major myofascial flap should become a standard technique in total laryngectomy for the prevention of pharyngocutaneous fistula.<sup>25</sup> Similarly, Gil *et al.* reported that the pectoralis major myofascial flap should be used judiciously as a surgical adjunct for buttressing the pharyngeal suture line in patients who are at a high risk for pharyngocutaneous fistula formation.8

There are several limitations related to the retrospective design of our study. The small number of patients who were enrolled in our study limits our ability to draw strong conclusions from the data. Our study confirmed that a greater percentage of the pharyngocutaneous fistulas in primary laryngectomy patients healed with conservative management and in a shorter time than in the salvage group. 19 In the salvage group with pectoralis major myofascial flap reinforcement, all of the fistulas healed with conservative management in a similar time to the primary laryngectomy patients. No significant difference was observed between the oral feeding day and length of hospital stay of patients who underwent primary laryngectomy and patients who underwent salvage laryngectomy with a pectoralis major myofascial flap. In the salvage group without a pectoralis major myofascial flap, 75 per cent of the fistulas required surgical closure with a pectoralis major myocutaneous flap after the initial surgery. This most probably can be attributed to the diminished healing capacity of the irradiated tissues secondary to decreased vascularity. Contrary to recent studies, our study demonstrated that pectoralis major myofascial flap reinforcement did not decrease the rate of pharyngocutaneous fistula formation. Instead, it prevented the formation of large fistulas, which would require surgical management, and it provided similar time to oral feeding and length of hospital stay to primary laryngectomy patients.

#### References

- 1 Rosai J. Ackerman's Surgical Pathology, 8th edn. St Louis: Mosby, 1996;319–23
- 2 Gillison ML, Forastiere AA. Larynx preservation in head and neck cancers. A discussion of the National Comprehensive Cancer Network Practice Guidelines. *Hematol Oncol Clin* North Am 1999;13:699–718
- 3 Hoffman HT, McCulloch T, Gustin D, Karnell LH. Organ preservation therapy for advanced-stage laryngeal carcinoma. Otolaryngol Clin North Am 1997;30:113–30
- 4 Moyer JS, Wolf GT, Bradford CR. Current thoughts on the role of chemotherapy and radiation in advanced head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg* 2004;**12**:82–7

- 5 Withrow KP, Rosenthal EL, Gourin CG, Peters GE, Magnuson JS, Terris DJ et al. Free tissue transfer to manage salvage laryngectomy defects after organ preservation failure. Laryngoscope 2007:117:781–4
- 6 Davidson BJ, Newkirk KA, Harter KW, Picken CA, Cullen KJ, Sessions RB. Complications from planned, posttreatment neck dissections. Arch Otolaryngol Head Neck Surg 1999;125:401–5
- 7 Sassler AM, Esclamado RM, Wolf GT. Surgery after organ preservation therapy. Analysis of wound complications. Arch Otolaryngol Head Neck Surg 1995;121:162–5
- 8 Gil Z, Gupta A, Kummer B, Cordeiro PG, Kraus DH, Shah JP et al. The role of pectoralis major muscle flap in salvage total laryngectomy. Arch Otolaryngol Head Neck Surg 2009;135: 1019–23
- 9 Applebaum EL, Levine HL. Pharyngeal reconstruction after laryngectomy. *Laryngoscope* 1977;87:1884–90
- 10 Berry SM, Fischer JE. Classification and pathophysiology of enterocutaneous fistulas. Surg Clin North Am 1996;76:1009–18
  11 Celikkanat S, Koç C, Akyol MU, Ozdem C. Effect of blood
- 11 Celikkanat S, Koç C, Akyol MU, Ozdem C. Effect of blood transfusion on tumor recurrence and postoperative pharyngocutaneous fistula formation in patients subjected to total laryngectomy. *Acta Otolaryngol* 1995;115:566–8
- 12 Sousa AA, Castro SM, Porcaro-Salles JM, Soares JM, de Moraes GM, Carvalho JR et al. The usefulness of a pectoralis major myocutaneous flap in preventing salivary fistulae after salvage total laryngectomy. Braz J Otorhinolaryngol 2012;78: 103-7
- 13 Tsou YA, Hua CH, Lin MH, Tseng HC, Tsai MH, Shaha A. Comparison of pharyngocutaneous fistula between patients followed by primary laryngopharyngectomy and salvage laryngopharyngectomy for advanced hypopharyngeal cancer. *Head Neck* 2010;32:1494–500
- 14 Ariyan S. The pectoralis major myocutaneous flap. A versatile flap for reconstruction in the head and neck. *Plast Reconstr Surg* 1979;63:73–81
- 15 Paydarfar JA, Birkmeyer NJ. Complications in head and neck surgery: A meta-analysis of postlaryngectomy pharyngocutaneous fistula. Arch Otolaryngol Head Neck Surg 2006;132: 67–72
- 16 Gooi Z, Richmon J. Long-term oral intake through a salivary bypass tube with chronic pharyngocutaneous fistula. Am J Otolaryngol 2012;33:762–3
- 17 Ganly I, Patel S, Matsuo J, Singh B, Kraus D, Boyle J et al. Postoperative complications of salvage total laryngectomy. Cancer 2005;103:2073–81

- 18 Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H et al. Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003;129:44-9
- 19 White HN, Golden B, Sweeny L, Carroll WR, Magnuson JS, Rosenthal EL. Assessment and incidence of salivary leak following laryngectomy. *Laryngoscope* 2012;122:1796–9
- 20 Patel UA, Keni SP. Pectoralis myofascial flap during salvage laryngectomy prevents pharyngocutaneous fistula. *Otolaryngol Head Neck Surg* 2009;**141**:190–5
- 21 Hanasono MM, Lin D, Wax MK, Rosenthal EL. Closure of laryngectomy defects in the age of chemoradiation therapy. *Head Neck* 2012;34:580–8
- 22 Furuta Y, Homma A, Oridate N, Suzuki F, Hatakeyama H, Suzuki K et al. Surgical complications of salvage total laryngectomy following concurrent chemoradiotherapy. Int J Clin Oncol 2008;13:521–7
- 23 Milenović A, Virag M, Uglesić V, Aljinović-Ratković N. The pectoralis major flap in head and neck reconstruction: First 500 patients. J Craniomaxillofac Surg 2006;34:340–3
- 24 Righini C, Lequeux T, Cuisnier O, Morel N, Reyt E. The pectoralis myofascial flap in pharyngolaryngeal surgery after radiotherapy. Eur Arch Otorhinolaryngol 2005;262:357–61
- 25 Smith TJ, Burrage KJ, Ganguly P, Kirby S, Drover C. Prevention of postlaryngectomy pharyngocutaneous fistula: The Memorial University experience. J Otolaryngol 2003;32: 222-5

Address for correspondence: Dr Ela Cömert Ankara Oncology Education and Research Hospital, Mehmet Akif Ersoy mah., 06200, Yenimahalle, Ankara Turkey

Fax: +90 312 345 49 79 E-mail: elacomert@yahoo.com

Dr E Cömert takes responsibility for the integrity of the content of the paper Competing interests: none declared